SCHEMBL4040912

SCHEMBL4040912

O=C(NC1CCCCC1)[C@@H](C1CCOCC1)C1(c2ccc(Cl)cc2)Nc2ccccc2N1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 5/20 0.49
CYP2C19 P33261 2/20 0.42
CYP3A4 P08684 1/20 0.42
EPHX1 P07099 3/20 0.39
ALDH1A1 P00352 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
POLB P06746 1/20 0.39
CYP2C9 P11712 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37
IDO1 P14902 1/20 0.37
KMT2A Q03164 1/20 0.37
P2RX7 Q99572 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4041029 1.00 NR1H4 (0.49) NR1H4CYP2C19CYP3A4EPHX1ALDH1A1
SCHEMBL4039448 0.97 NR1H4 (0.48) NR1H4CYP2C19CYP3A4EPHX1ALDH1A1
SCHEMBL4039874 0.97 NR1H4 (0.48) NR1H4CYP2C19CYP3A4EPHX1ALDH1A1
SCHEMBL4042732 0.94 NR1H4 (0.44) NR1H4CYP2C19CYP3A4EPHX1ALDH1A1
SCHEMBL4039101 0.94 NR1H4 (0.44) NR1H4CYP2C19CYP3A4EPHX1ALDH1A1
SCHEMBL4040480 0.92 NR1H4 (0.44) NR1H4CYP2C19CYP3A4EPHX1ALDH1A1
SCHEMBL4044540 0.92 NR1H4 (0.44) NR1H4CYP2C19CYP3A4EPHX1ALDH1A1
SCHEMBL4040768 0.90 NR1H4 (0.43) NR1H4CYP2C19CYP3A4EPHX1ALDH1A1
SCHEMBL4038576 0.90 NR1H4 (0.43) NR1H4CYP2C19CYP3A4EPHX1ALDH1A1
SCHEMBL4035519 0.89 NR1H4 (0.42) NR1H4CYP2C19CYP3A4EPHX1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed